Tarsus Pharmaceuticals Management
Management criteria checks 4/4
Tarsus Pharmaceuticals' CEO is Bobby Azamian, appointed in Nov 2016, has a tenure of 7.92 years. total yearly compensation is $3.13M, comprised of 19.8% salary and 80.2% bonuses, including company stock and options. directly owns 2.24% of the company’s shares, worth $39.90M. The average tenure of the management team and the board of directors is 3.5 years and 4.1 years respectively.
Key information
Bobby Azamian
Chief executive officer
US$3.1m
Total compensation
| CEO salary percentage | 19.8% |
| CEO tenure | 8yrs |
| CEO ownership | 2.2% |
| Management average tenure | 3.5yrs |
| Board average tenure | 4.1yrs |
Recent management updates
Recent updates
US$65.33 - That's What Analysts Think Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Is Worth After These Results
Nov 16
Investors Appear Satisfied With Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Prospects As Shares Rocket 41%
Nov 07Here's Why Tarsus Pharmaceuticals (NASDAQ:TARS) Can Manage Its Debt Despite Losing Money
Nov 05Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stocks Shoot Up 35% But Its P/S Still Looks Reasonable
Sep 05Tarsus Pharmaceuticals: Strong Execution In Eye Disease Treatment
Aug 20With A 26% Price Drop For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) You'll Still Get What You Pay For
Jun 26Following Up On Tarsus Pharmaceuticals
May 28Analysts Are Upgrading Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) After Its Latest Results
May 11Tarsus Pharmaceuticals: A Strong Launch For An Under The Radar Name
Mar 08Rainbows and Unicorns: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Analysts Just Became A Lot More Optimistic
Mar 03Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Mar 01Is Tarsus Pharmaceuticals (NASDAQ:TARS) A Risky Investment?
Feb 28New Forecasts: Here's What Analysts Think The Future Holds For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
Nov 12What Does The Future Hold For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)? These Analysts Have Been Cutting Their Estimates
Aug 16CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$134m |
| Jun 30 2024 | n/a | n/a | -US$150m |
| Mar 31 2024 | n/a | n/a | -US$148m |
| Dec 31 2023 | US$3m | US$620k | -US$136m |
| Sep 30 2023 | n/a | n/a | -US$108m |
| Jun 30 2023 | n/a | n/a | -US$91m |
| Mar 31 2023 | n/a | n/a | -US$65m |
| Dec 31 2022 | US$4m | US$590k | -US$62m |
| Sep 30 2022 | n/a | n/a | -US$63m |
| Jun 30 2022 | n/a | n/a | -US$56m |
| Mar 31 2022 | n/a | n/a | -US$44m |
| Dec 31 2021 | US$7m | US$550k | -US$14m |
| Sep 30 2021 | n/a | n/a | -US$10m |
| Jun 30 2021 | n/a | n/a | -US$5m |
| Mar 31 2021 | n/a | n/a | -US$15m |
| Dec 31 2020 | US$3m | US$437k | -US$27m |
| Sep 30 2020 | n/a | n/a | -US$17m |
| Jun 30 2020 | n/a | n/a | -US$7m |
| Mar 31 2020 | n/a | n/a | -US$5m |
| Dec 31 2019 | US$416k | US$300k | -US$5m |
Compensation vs Market: Bobby's total compensation ($USD3.13M) is below average for companies of similar size in the US market ($USD5.38M).
Compensation vs Earnings: Bobby's compensation has been consistent with company performance over the past year.
CEO
Bobby Azamian
8yrs
Tenure
US$3,130,332
Compensation
Dr. Bobak R. Azamian, also known as Bobby, MD, Ph D, DPhil, is Co-Founder of Tarsus Pharmaceuticals, Inc. and serves as its President since November 2016. He serves as Chief Executive Officer at Tarsus Pha...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 8yrs | US$3.13m | 2.24% $ 39.9m | |
| CFO & Chief Strategy Officer | 1.6yrs | US$3.99m | 0.047% $ 844.7k | |
| Chief Operating Officer | 4.3yrs | US$1.74m | 0.17% $ 3.0m | |
| Chief Medical Officer | 4.3yrs | US$180.21k | 0.087% $ 1.5m | |
| Head of Investor Relations | 3.2yrs | no data | no data | |
| General Counsel & Corporate Secretary | 3.8yrs | US$2.53m | 0.11% $ 1.9m | |
| Senior Director of Corporate Communications | 2.6yrs | no data | no data | |
| Vice President of Marketing | 2.8yrs | no data | no data | |
| Vice President of Sales | 2.7yrs | no data | no data | |
| Chief Human Resources Officer | 3.8yrs | US$3.21m | 0.089% $ 1.6m | |
| Chief Commercial Officer | 4.3yrs | no data | 0.14% $ 2.5m | |
| Senior Vice President of Corporate Affairs | 1.1yrs | no data | no data |
3.5yrs
Average Tenure
46yo
Average Age
Experienced Management: TARS's management team is considered experienced (3.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 7.9yrs | US$3.13m | 2.24% $ 39.9m | |
| Independent Director | 7.8yrs | US$183.33k | 0.46% $ 8.3m | |
| Lead Independent Director | 4yrs | US$265.83k | 0.027% $ 482.2k | |
| Independent Director | 4.9yrs | US$178.58k | 0.014% $ 249.3k | |
| Independent Director | 2.1yrs | US$186.46k | 0.016% $ 280.3k | |
| Independent Director | 3.3yrs | US$183.71k | 0.014% $ 249.3k | |
| Independent Director | 4.3yrs | US$171.71k | 0.017% $ 295.8k | |
| Director | no data | no data | no data |
4.1yrs
Average Tenure
67.5yo
Average Age
Experienced Board: TARS's board of directors are considered experienced (4.1 years average tenure).